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Abstract     
Whole genome sequence of the human pathogen Chlamydophila pneumoniae and 
four other strains of same species were analyzed to identify drug targets. Total number 
4388 protein coding genes were studied from four strains; in which 3948 genes were 
having more than 100 amino acids in their coding sequence were selected; we found 147 
genes were identified as non-human homologs and conserved proteins among four strains. 
These non-human homologs genes and their encoding protein were categorized on the 
basis of the pathways involved in the basic survival mechanisms of the bacterium. Further, 
MSA of these genes showed eight different types of proteins as a novel drug target to 
design a drug. The modeled Holliday junction DNA helicase RuvB protein has more 
appropriate active sites among all other target proteins. Though all chosen drugs bind to 
Holliday junction DNA helicase RuvB protein, the binding site on the target protein with 
the minimum binding energy was selected. By using the active site prediction tools, under 
the optimized conditions we designed a set of antibiotics. Docking was done with the 
Autodock 4.0 with the different conformations of each ligand. This is the better drug that 
binds to the active site of target protein and inhibits their activities, which will effects one 
of the most essential pathways involved in DNA replication, recombination, modification 
and repair. Therefore, this in silico analysis provides rapid and potential approach for 
identification of drug target and designing of drug.  
Keywords: Chlamydophila pneumoniae, homology modeling, drug targets, docking, drug 
design, Holliday junction DNA helicase Ruv-B, MSA (Multiple Sequence Alignment). 
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Introduction: 
The growing number of microbial genome sequencing projects has generated a 
large number of sequences. To date, sequence information from approximately 400 
complete genomes has been deposited into various public domains, completion of the 
human genome project has revolutionised the field of drug-discovery against threatening 
human pathogens.  These data pose a major challenge in the post-genomic era, i. e. to 
fully exploit this treasure trove for the identification and characterization of virulent 
factors in these pathogens, and to identify novel putative targets for therapeutic 
intervention [1]. 
The strategies for drug design and development are progressively shifting from the 
genetic approach to the genomic approach [2]. Novel drug targets are required in order to 
design new defense against antibiotic sensitive pathogens. Comparative genomics and 
bioinformatics provide new opportunities for finding optimal targets among previously 
unexplored cellular functions based on an understanding of their related biological 
processes in bacterial pathogens and their hosts.  
The genome information is also useful in the identification, validation, selection of 
the potential candidates and screening based on "essentiality" and "selectivity" criteria of 
the microbial systems [3]. The target must be essential for the growth, replication, 
viability or survival of the microorganism, i. e. encoded by genes critical for pathogenic 
life-stages. The microbial target for treatment should not have any well-conserved 
homolog in the host, in order to address cytotoxicity issues. This can help to avoid 
expensive dead-ends later drug discovery process. Genes that are conserved in different 
genomes often turn out to be essential. A gene is deemed to be essential if the cell cannot 
tolerate its inactivation by mutation, and its status is confirmed using conditional lethal 
mutants. A good candidate is a gene essential for bacteria survival, yet cannot be found in 
the mammalian host [4]. Inactivation of essential genes results in the lethal phenotype in 
the bacteria [5] and these drugs should function as a ‘magic bullet’ against bacteria. This 
would help to avoid costly dead-ends when a lead target is identified and investigated in 
great detail to find all its inhibitors are invariably toxic for humans[6]. 
The possibilities of selecting targets through genomics-related methodologies are 
increasing. An interesting approach designated "differential genome display" has been 
proposed for the prediction of potential drug targets[7,8]. This approach relies on the fact 
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that genomes of parasitic microorganisms are generally much smaller and encode fewer 
proteins than the genomes of free-living organisms. The genes that are present in the 
genome of a parasitic bacterium, but absent in the genome of a closely related free-living 
bacterium, are therefore likely to be important for pathogenicity and may be considered 
candidate drug targets. A complementary approach to target identification by 
bioinformatics was reported in a concordance analysis of microbial genomes. A simple 
and efficient computational tool was developed that can determine concordances of 
putative gene products showing sets of proteins conserved across one set of user-specified 
genomes, but are not present in another set of user-specified genomes. The functions 
encoded by essential genes are considered to constitute the foundation of life of the 
organism, and are therefore likely to be common to all cells. Identification and 
characterization of essential genes for the establishment and/or maintenance of infection 
may be the basis to elaborate novel and effective antimicrobials against bacteria, 
especially if these genes are conserved in various bacterial pathogens, suggested searching 
for drug targets among previously characterized proteins that are specific and essential for 
a particular pathogen. Recently,compiled a list of all currently available essential genes 
into the Database of Essential Genes (DEG)[9], which includes the essential genes 
identified in the genomes of Mycoplasma genitalium, Haemophilus influenzae, Vibrio 
cholerae, Staphylococcus aureus, Escherichia coli, Helicobacter pylori, Bacillus subtilis, 
Mycobacterium tuberculosis H37Rv, Streptococcus pneumoniae, Salmonella typhimurium 
and Saccharomyces cerevisiae. Concurrently, the recent availability of the human genome 
sequence represents a major step in drug discovery. These resources provide a basis for 
addressing the "complexities and conundrums" in drug discovery by computational 
methods. The application of a subtractive genomics approach for the identification of 
essential genes that may be considered as candidates for antibacterial drug discovery, 
using the completely sequenced bacteria.  
Subtractive genomics has been successfully used by authors to locate novel drug 
targets in Pseudomonas aeruginosa [3]. The work has been effectively complemented 
with the compilation of the Database of Essential Genes (DEG) for a number of 
pathogenic microorganims. Concurrently, the recent availability of the human genes can 
eliminate potential drug targets that have close human homologs.  
Whole genome sequence of the human pathogen Chlamydophila pneumoniae and 
four other strains of same species were analyzed to identify drug targets. Furthermore, we 
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were successfully identified a number of promising drug targets, among these targets we 
are taken DNA helicase RuvB protein for new antibiotic development. DNA helicase 
RuvB protein involved in the repair of DNA, DNA recombination and in an SOS 
response. Unknown structure protein can be predicated computationally by using different 
algorithm. Homology modeling builds on the observation that the three-dimensional 
structure of proteins is better conserved during evolution than its sequence [10].  
Protein performs its function through interaction with other molecules such as 
substrate, ligand, DNA and other domains of proteins. The three-dimensional structure of 
protein provides the necessary shape and physicochemical texture to facilitate these 
interactions. Structural information of protein surface regions enables detailed studies of 
the relationship of protein structure and function. Specifically, characterization of protein 
surface regions helps to analyze enzyme mechanism, to determine binding specificity and 
to plan mutation studies. It can also help to identify the biological roles of newly solved 
protein structures with an unknown function. 
The identification and visualization of protein cavities is the starting point for 
many structure-based drug design (SBDD) applications. Sites of activity in proteins 
usually lie in cavities, where the binding of a substrate typically serves as a mechanism for 
triggering some event, such as a chemical modification or conformational change. 
Consequently, binding sites are often targeted in attempts to interrupt molecular processes 
via therapeutics. Although binding site locations are often furnished by x-ray data or fold 
recognition, tools that automatically predict these locations have become quite popular in 
SBDD, especially as front-ends to molecular docking or when alternate binding sites are 
sought [11, 12]. The size and shape of protein cavities dictates the three-dimensional 
geometry of ligands that can strongly bind there; i.e. they must fit like a hand in glove. 
Thus, a minimal requirement for drug activity is that the molecule sterically fit the region 
of buried volume inscribing the active site cavity, with some allowance for induced fit. 
The determination and visualization of these volumes is critical in drug design, 
particularly since manual intervention is still fruitfully employed in most design scenarios. 
An ordinary stick representation of a protein, unfortunately, provides little insight 
regarding the location, shape, or size of its buried volumes. While surface representations 
[13, 14] are a step in the right direction, they still fall short in that they require the user to 
infer buried volumes from often-occluded void space. Consequently, methods for direct 
display of regions of buried volume in proteins have become prevalent in recent years 
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[15]. Moreover, as molecular docking and virtual screening become more predictive and 
prevalent, the possibility of interfacing such tools with functional genomics via threading 
or homology modeling becomes increasingly tempting. A versatile tool like PASS, 
CASTp that can rapidly predict binding sites should, therefore, find a niche as a front-end 
to such automated screening efforts. 
Protein-ligand docking methods aim to predict the binding energy of the protein-
ligand complex given the atomic coordinates. Recent improvements in search algorithms 
and energy functions, computational docking methods have become a valuable tool to 
probe the interaction between protein and its inhibitors. The interaction energy between 
the protein and its ligand is calculated by a simplified, often grid-based force field [16]. 
Generally various docking methods followed by various energy scoring functions. Basic 
components may include steric and electrostatic energies, sometimes supplemented by 
other terms accounting for hydrogen bonding and salvation effects. Gibbs free energy of 
binding is ∆G then related to the binding constant by ∆G0=-RTlnKi  At best, ∆G is 
determined by statistical thermodynamics resulting in a master equation that considers all 
contributing effects. 
This can be written out conceptually by the following equation. 
                ∆GBinding= ∆GMotion+ ∆GInteraction+ ∆GSolvent+ ∆GCofiguration 
The accurate prediction of enzyme-substrate interaction energies is one of the 
major challenges in computational biology.   
Active sites of a protein are key factor for the flexible docking. Autodock4.0 [17]. 
is an automated docking tool that was designed to predict how small molecules bind to 
receptor of known 3D structure and it also optionally enables to model Binding parameters 
of ligand with number of distinct conformational clusters and to find all possible minimum 
binding energy. 
 
 
6
Chapter 2 
 
 
 
 
LITERATURE REVIEW  
2.1    Chlamydia Pneumoniae…………………………………………7 
2.1.1 Life Cycle of Chlamydophila Pneumoniae…………………...8 
2.1.2 Pneumonia Caused By Chlamydophila Pneumoniae………......9 
2.1.3 Symptoms and Diagnosis………………………………….10 
2.1.4 Treatment and Prognosis…………………………………..10 
2.1.5 Epidemiology and Prevention……………………………...11 
2.2 Protein Structure Prediction and Modelling………………..………..11 
2.2.1 Protein structure prediction Methods………………………..12 
2.2.2 Homology Modelling ……………………………………. 12 
2.2.3 Steps In Homology Modelling ……………………………..13 
2.3 Structure Analysis and active site prediction ……………………….14 
2.3.1 Ramachandran plot………………………………………. 14 
2.3.2 Sidechains………………………………………………..17 
 
 
7
2.1 Chlamydia Pneumoniae: 
Chlamydia pneumoniae is a common obligate intracellular bacterium that causes 
upper and lower respiratory infections worldwide [18]. In addition to acute infections, 
several chronic inflammatory diseases have been presumptively associated with 
C. pneumoniae infection. Increasing evidence implicates that a persistent lung infection 
caused by C. pneumoniae may contribute to the initiation, exacerbation and promotion of 
asthma symptoms. A causal association between C. pneumoniae infection and asthma is 
biologically plausible based on the observations that asthma is a chronic inflammatory 
disease of the airways, and that Chlamydia are known to produce chronic inflammatory 
damage in target organs. Whether C. pneumoniae lung infections activate the same 
immunopathologic mechanisms that have been demonstrated for other chlamydial diseases 
has not been explored systematically. Chlamydophila pneumoniae also infects and causes 
disease in Koalas, emerald tree boa (Corallus caninus), iguanas, chameleons, frogs and 
turtles. 
C pneumoniae. causes infection approximately 50% of young adults and 75% of 
elderly persons have serological evidence of previous infection. The pathogen is estimated 
to cause 3-10% of community-acquired pneumonia cases among adults. The estimated 
number of cases of C pneumoniae pneumonia is 300,000 cases per year[19].  
C. pneumoniae infection has also been linked with atherosclerosis — another 
chronic inflammatory disease. Since then, a large number of seroepidemiological studies 
have confirmed these findings. The actual presence of C. pneumoniae in atherosclerotic 
lesions has also been demonstrated in a number of studies and by various methods. 
Moreover, the presence of C. pneumoniae-specific T lymphocytes in atherosclerotic tissue 
specimens suggests that C. pneumoniae participates in the maintenance of the 
inflammatory response in the tissue and may thus be involved in the progression of the 
disease. In experimental animals, C. pneumoniae infection has been found to induce 
inflammatory changes and calcified lesions containing Chlamydia  and to accelerate the 
development of atherosclerosis. 
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Table1: The complete genome information about C. pneumoniae strains from NCBI. 
Tax name  C.P_AR39 C.P_CWL029 C.P_J138 C.P_TW183 
Accession NC_002179.2 NC_000922.1 NC_002491.1 NC_005043.1 
GI 58021288 15617929 15835535 33241335 
Tax id 115711 115713 138677 182082 
Genome_ID 154 140 160 311 
DNA  length 1229853 1230230 1226565 1225935 
Genetic Code 11 11 11 11 
Publications 10684935 10192388 10871362 10452345 
Protein count 1112 1052 1069 1113 
CDS count 1112 1052 1069 1113 
RNA count 41 43 41 41 
Gene count 1167 1122 1110 1155 
Others 0 2 0 2 
Total 2320 2219 2220 2311 
 
2.1.1 Life cycle of Chlamydophila pneumoniae 
Chlamydophila pneumoniae is a small bacterium (0.5 micrometres) that undergoes 
several transformations during its life cycle. It exists as an elementary body (EB) in 
between hosts. The EB is not biologically active but is resistant to environmental stresses 
and can survive outside of a host. The EB travels from an infected person to the lungs of a 
non-infected person in small droplets and is responsible for infection. Once in the lungs, 
the EB is taken up by cells in a pouch called an endosome by a process called 
phagocytosis. However, the EB is not destroyed by fusion with lysosomes as is typical for 
phagocytosed material. Instead, it transforms into a reticulate body and begins to replicate 
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within the endosome. The reticulate bodies must utilize some of the host's cellular 
machinery to complete its replication. The reticulate bodies then convert back to 
elementary bodies and are released back into the lung, often after causing the death of the 
host cell. The EBs are thereafter able to infect new cells, either in the same organism or in 
a new host. Thus, the life cycle of Chlamydophila pneumoniae is divided between the 
elementary body which is able to infect new hosts but cannot replicate and the reticulate 
body which replicates but is not able to cause new infection. 
 
Fig.1: Developmental life cycle of Chlamydia  
2.1.2 Pneumonia caused by Chlamydophila pneumoniae 
Chlamydophila pneumoniae is a common cause of pneumonia around the world. 
Chlamydophila pneumoniae is typically acquired by otherwise healthy people and is a 
form of community-acquired pneumonia. Because treatment and diagnosis are different 
from historically recognized causes such as Streptococcus pneumoniae, pneumonia caused 
by Chlamydophila pneumoniae is categorized as an "atypical pneumonia." 
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2.1.3 Symptoms and diagnosis 
Symptoms of infection with Chlamydophila pneumoniae are indistinguishable from 
other causes of pneumonia. These include cough, fever, and difficulties breathing. 
Chlamydophila pneumoniae more often causes pharyngitis, laryngitis, and sinusitis than 
other causes of pneumonia; however, because many other causes of pneumonia results in 
these symptoms, differentiation is not possible. Likewise, a physical examination by a 
health provider does not typically provide information which allows for a definite 
diagnosis. 
Diagnosis of Chlamydophila pneumoniae may be confounded by prior infections with 
this microorganism. Examination of sputum or the secretions of the respiratory tract may 
reveal signs of the bacteria. Otherwise, examination of the blood may reveal antibodies 
against the bacteria. If there has been a prior infection, this may have resulting in pre-
existing antibodies. Therefore, interpretation may require a period of six weeks in order to 
reanalyze the antibodies and to determine whether the infection was new or old. 
Examination of the blood may also show proteins (antigens) from Chlamydophila 
pneumoniae, either through direct fluorescent antibody testing, enzyme-linked 
immunosorbent assay (ELISA), or polymerase chain reaction (PCR). 
Chest x-rays of lungs infected with Chlamydophila pneumoniae often show a small 
patch of increased shadow (opacity). However, many different patterns are common and 
there is no appearance which allows for a specific diagnosis. 
2.1.4 Treatment and prognosis 
Typically, treatment for pneumonia is begun before the causative microorganism is 
identified. This empiric therapy includes an antibiotic active against the atypical bacteria, 
including Chlamydophila pneumoniae. The most common type of antibiotic used is a 
macrolide such as azithromycin or clarithromycin. If testing reveals that Chlamydophila 
pneumoniae is the causative agent, therapy may be switched to doxycycline, which is 
slightly more effective against the bacteria. Sometimes a quinolone antibiotic such as 
levofloxacin may be started empirically. This group is not as effective against 
Chlamydophila pneumoniae. Treatment is typically continued for ten to fourteen days for 
known infections. 
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Prognosis of pneumonia caused by Chlamydophila pneumoniae is excellent. 
Hospitalization is uncommon, complications are rare, and most people have no residual 
deficits. In fact, Chlamydophila pneumoniae is a common cause of walking pneumonia, so 
named because most people are able to continue to walk and participate in reduced activity 
during infection. 
2.1.5 Epidemiology and prevention 
Chlamydophila pneumoniae affects all age groups and is most common among the 60-
79 year old age group. Reinfection is common after a short period of immunity. The 
incidence is one case out of one thousand per year and causes ten percent of community-
acquired pneumonias treated without hospitalization.[citation needed] As of 2005, there 
are no vaccines or other ways to prevent infection other than good hygiene and healthy 
eating as well as active lifestyle some people with obesity face the same symptoms, a 
stress free life as well as active and conscious living are the best viral and physical 
prevention known. 
2.2 Protein structure prediction and modeling 
The ultimate goal of protein modeling is to predict a structure from its sequence 
with an accuracy that is comparable to the best results achieved experimentally. Most 
attempts to predict protein structure from basic physical principles alone try to reproduce 
the interatomic interactions in proteins, to define a computable energy associated with any 
conformation. Computationally, the problem of protein structure prediction then becomes 
a task of finding the global minimum of this conformational energy function. So far this 
approach has not succeeded, partly because of the inadequacy of the energy function and 
partly because the minimization algorithms tend to get trapped in local minima. 
Other approaches to structure prediction are based on attempts to simplify the 
problem, to capture somehow the essentials. The alternative to a priori methods are 
approaches based on assembling clues to the structure of a target sequence by finding 
similarities to known structures. These empirical or 'knowledge-based' methods are 
becoming very powerful[20]. 
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2.2.1 Protein structure prediction Methods 
Methods for prediction of protein structure from amino acid sequence include: 
1) Attempts to predict secondary structure without attempting to assemble these 
regions in three- dimensions. The results are lists of regions of the sequence 
predicted to form α-helices and regions predicted to form strands of β-sheet. 
2) Homology modelling: prediction of the three-dimensional structure of a protein 
from the known structures of one or more related proteins. The results are a 
complete coordinate set for mainchain and sidechains, intended to be a high-
quality model of the structure, comparable to at least a low-resolution 
experimental structure. 
3) Fold recognition: given a library of known structures, determine which of them 
shares a folding pattern with a query protein of known sequence but unknown 
structure. If the folding pattern of the target protein does not occur in the library, 
such a method should recognize this. The results are a nomination of a known 
structure that has the same fold as the query protein, or a statement that no protein 
in the library has the same fold as the query protein. 
4)  Prediction of novel folds, either by a priori or knowledge-based methods. The 
results are a complete coordinate set for at least the mainchain and sometimes the 
sidechains also. The model is intended to have the correct folding pattern, but 
would not be expected to be comparable in quality to an experimental structure. 
2.2.2 Homology modelling 
Model-building by homology is a useful technique when one wants to predict the 
structure of a target protein of known sequence, when the target protein is related to at 
least one other protein of known sequence and structure. If the proteins are closely related, 
the known protein structures - called the parents - can serve as the basis for a model of the 
target. Although the quality of the model will depend on the degree of similarity of the 
sequences, it is possible to specify this quality before experimental testing.  In 
consequence, knowing the quality of the model required for the intended application 
permits intelligent prediction of the probable success of the exercise. 
 
 
 
13
2.2.3 Steps in Homology Modelling 
1. Align the amino acid sequences of the target and the protein or proteins of known  
structure. It will generally be observed that insertions and deletions lie in the loop regions 
between helices and sheets. 
2. determine mainchain segments to represent the regions containing insertions or 
deletions. Stitching these regions into the mainchain of the known protein creates a model 
for the complete mainchain of the target protein. 
3. Replace the sidechains of residues that have been mutated. For residues that have not 
mutated, retain the sidechain conformation. Residues that have mutated tend to keep the 
same sidechain conformational angles, and could be modelled on this basis. However, 
computational methods are now available to search over possible combinations of 
sidechain conformations. 
4. Examine the model - both by eye and by programs - to detect any serious collisions 
between atoms. Relieve these collisions, as far as possible, by manual manipulations. 
5. Refine the model by limited energy-minimization. The role of this step is to fix up the 
exact geometrical relationships at places where regions of mainchain have been joined 
together, and to allow the sidechains to wriggle around a bit to place themselves in 
comfortable positions. The effect is really only cosmetic - energy refinement will not fix 
serious errors in such a model. 
In a sense, this procedure produces 'what you get for free' in that it defines the 
model of the protein of unknown structure by making minimal changes to its known 
relative. Unfortunately, it is not easy to make substantial improvements. A rule of thumb 
is that if the two sequences have at least 40–50% identical amino acids in an optimal 
alignment of their sequences, the procedure described will produce a model of sufficient 
accuracy to be useful for many applications. If the sequences are more distantly related, 
neither the procedure described nor any other currently available method will produce a 
model, correct in detail, of the target protein from the structure of its relative. 
In most families of proteins the structures contain relatively constant regions and 
more variable ones. The core of the structure of the family retains the folding topology, 
although it may be distorted, but the periphery can entirely re-fold. A single parent 
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structure will permit reasonable modelling of the conserved portion of the target protein, 
but will fail to produce a satisfactory model of the variable portion. Moreover, it will not 
be easy to predict which are the variable and constant regions. A more favourable 
situation occurs when several related proteins of known structure can serve as parents for 
modelling a target protein. These reveal the regions of constant and variable structure in 
the family. The observed distribution of structural variability among the parents dictates 
an appropriate distribution of constraints to be applied to the model. 
2.3 Structure Analysis and active site prediction  
The stereochemical validation of model structures of proteins is an important part 
of the comparative molecular modeling process. Firstly, the selection of high quality 
structures for inclusion in loop dictionaries is important for the simple reason that these 
coordinate sets will be used to build future models. Secondly, the structural evaluation of 
comparative modeling output must be used to identify possible problematic regions [21]. 
There is some measurements are good indicators of stereochemical quality; these 
include planarity; chirality; phi/psi preferences; chi angles; non-bonded contact distances; 
unsatisfied donors and acceptors. 
Protein performs its function through interaction with other molecules such as 
substrate, ligand, DNA and other domains of proteins. The three-dimensional structure of 
protein provides the necessary shape and physicochemical texture to facilitate these 
interactions. Structural information of protein surface regions enables detailed studies of 
the relationship of protein structure and function. Specifically, characterization of protein 
surface regions helps to analyze enzyme mechanism, to determine binding specificity and 
to plan mutation studies. It can also help to identify the biological roles of newly solved 
protein structures with an unknown function 
2.3.1 Ramachandran plot 
The Sasisekharan-Ramakrishnan-Ramachandran plot describes allowed mainchain 
conformations. A Ramachandran plot is a way to visualize dihedral angles φ against ψ of 
amino acid residues in protein structure. It shows the possible conformations of φ and ψ 
angles for a polypeptide [22]. 
A fragment of the linear polypeptide chain common to all protein structures is 
shown in Fig.2 Rotation is permitted around the N-Cα and Cα-C single bonds of all 
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residues (with one exception: proline). The angles φ and ψ around these bonds, and the 
angle of rotation around the peptide bond, ω, define the conformation of a residue. The 
peptide bond itself tends to be planar, with two allowed states: trans, ω ≈ 180° (usually) 
and cis, ω ≈ 0° (rarely, and in most cases at a proline residue). The sequence of φ, ψ and ω 
angles of all residues in a protein defines the backbone conformation. 
 
Fig.2: Definition of conformational angles of the polypeptide backbone. 
The principle that two atoms cannot occupy the same space limits the values of 
conformational angles. The allowed ranges of φ and ψ, for ω = 180°, fall into defined 
regions in a graph called Sasisekharan- Ramakrishnan-Ramachandran plot - usually 
shortened to 'Ramachandran plot' (see Fig. 3). Solid lines in the figure delimit energetically-
preferred regions of φ and ψ; broken lines in the figure delimit sterically-disallowed regions. 
The conformations of most amino acids fall into either the αR or β regions. Glycine has 
access to additional conformations. In particular it can form a left-handed helix: αL. Fig. 3 
shows the typical distribution of residue conformations in a well-determined protein 
structure. Most residues fall in or near the allowed regions, although a few are forced by the 
folding into energetically less-favourable states. 
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Fig.3: A Sasisekharan-Ramakrishnan-Ramachandran plot of acylphosphatase (PDB code 
2ACY). Note the clustering of residues in the α and β regions, and that most of the 
exceptions occur in Glycine residues (labeled G). 
The allowed regions generate standard conformations. A stretch of consecutive 
residues in the α conformation (typically 6–20 in native states of globular proteins) 
generates an α-helix. Repeating the β conformation generates an extended β-strand. Two or 
more β-strands can interact laterally to form β-sheets. Helices and sheets are 'standard' or 
'prefabricated' structural pieces that form components of the conformations of most 
proteins. They are stabilized by relatively weak interactions, hydrogen bonds, between 
mainchain atoms. In some fibrous proteins all of the residues belong to one of these types 
of structure: wool contains α-helices; silk β-sheets.  
 
 Typical globular proteins contain several helix and/or sheet regions, connected by 
turns. Usually the ends of helix or strand regions appear on the surface of a domain of a 
protein structure. They are connected by turns, or loops: regions in which the chain alters 
direction to point back into the structure. Many but not all turns are short, surface-exposed 
regions that tend to contain charged or polar residues.  Interactions involving sidechains 
must determine the mainchain conformation. 
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2.3.2 Sidechains 
Sidechains offer the physicochemical versatility required to generate all the different 
folding patterns. The sidechains of the twenty amino acids vary in: 
 Size: The smallest, glycine, consists of only a hydrogen atom; one of the largest, 
phenylalanine, contains a benzene ring. 
 Electric charge: Some sidechains bear a net positive or negative charge at normal 
pH. Asp and Glu are negatively charged, Lys and Arg are positively charged. 
(Charged residues of opposite sign can form attractive pairwise interactions called 
salt bridges.) 
 Polarity: Some sidechains are polar; they can form hydrogen bonds to other polar 
sidechains, or to the mainchain, or to water. Other sidechains are electrically 
neutral. Some of these contain chemical groups related to ordinary hydrocarbons 
such as methane or benzene. Because of the thermodynamically unfavourable 
interaction of hydrocarbons with water, these are called 'hydrophobic' residues, is 
an important contribution to protein stability.  
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3.1 Sequence alignments Tools 
Sequence alignments provide a powerful way to compare novel sequences with previously 
characterized genes. Both functional and evolutionary information can be inferred from 
well designed queries and alignments. BLAST (Basic Local Alignment Search Tool), 
provides a method for rapid searching of nucleotide and protein databases. Since the 
BLAST algorithm detects local as well as global alignments, regions of similarity 
embedded in otherwise unrelated proteins can be detected. Both types of similarity may 
provide important clues to the function of uncharacterized proteins. 
5 different versions of BLAST are 
BLASTn –compares a nucleotide query sequence against a nucleotide sequence database. 
BLASTp- compares a amino acid query seq. against a protein seq. database. 
BLASTx- compares a 6 framed conceptual translation product of a nucleotide query seq. 
against the protein seq. database(ultimately protein is compared) 
tBLASTn- compares a protein query seq. against a nucleotide seq. database. Dynamically 
translated in all the 6 reading frames. 
tBLASTx- compares 6 framed(6 forms) translation of a nucleotide query seq. against 6 
framed translation of a nucleotide seq. database. 
3.2 On Line Homology Modelling Softwares 
Swiss model (www.expasy.ch/swissmod/ SWISS-MODEL.html) is a fully automated 
protein structure Homology Modeling server. It has a first approach mode that helps 
performs Homology Modeling. The user has to enter his / her email id and input the 
protein sequence in Fasta format. It allows the user to choose the BLAST limit for 
template selection. It can search the pdb file from the pdb database with the user 
providing the name of the pdb file or the user can upload his / her own pdb file. The 
output file is a pdb file that is returned to the user's  email address. The result can be 
forwarded by Swiss Model to PHD Secondary structure prediction at Columbia University 
and Fold Recognition Server (3D-pssm) of the ICRF. Swiss Model however does not 
accept the sequences for homology modelling when similarity is less than 25%[23]. 
Geno3D (http://geno3d-pbil.ibcp.fr) performs Comparative protein structure Modeling by 
spatial restraints (distances and dihedral) satisfaction. Geno3D is most frequently used for 
Homology or Comparative protein structure Modeling.Geno3d accepts input similar to 
Fasta format but only the one letter code has to be used. The result is obtained in the pdb 
format that can be viewed in any Molecular Modeling software.Geno3d offers many other 
features, it allows the user to select PDB entries as templates for Molecular Modeling after 
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a 3 step iterative PSI BLAST. It presents the output for each template, along with the 
secondary structure prediction, displays percent of agreement in secondary structure and 
repartition of information from template on query sequence. The output link is sent to the 
user's email address. It also notifies the user when it's server begins the Homology 
Modeling. It has an option where the user can decide how many models to generate. The 
main idea behind having more than one model generated is that the user may have a better 
flexibility and understanding. It also returns a superimposed pdb file which has the models 
superimposed on each other. This is one of the good points in Geno3d as it allows us to 
compare the various models generated in one window. All the results obtained can be 
downloaded as a archive.tar.Z that can be opened in WinZip in windows and in UNIX or 
Linux platforms. So the user does not have to save results in webpage effect or in a 
document file. It also displays the Ramachandran plot in the result[24]. 
CPHmodels Automated neural-network based protein modeling server 
(Http://www.cbs.dtu.dk/services/CPHmodels/). CPHmodels is a collection of databases 
and methods developed to predict protein structure. It performs prediction of protein 
structure using Comparative Modeling. It does not accept more than 900 amino acids in 
the input sequence. The sequences are kept confidential and are deleted after processing. 
This program did not give me appropriate results. The error it displayed was similar to the 
one displayed by Swiss Model[25]. 
3.3 Offline Homology Modelling Software: 
MODELLER is used for homology or comparative modeling of protein three-
dimensional structures. It is built in FORTRAN. It will runs on python script file 
commands. Modeller is most frequently used for homology or comparative protein 
structure modeling. Modeller helps determine the spatial restraints from the templates. It 
generates a number of 3D models of the sequence you submit satisfying the template 
restraints. MODELLER automatically calculate a full-atom model. MODELLER models 
protein 3D structure keeping in the constraints of spatial restraints. The restraints can be 
derived from a number of different sources. These include NMR experiments (NMR 
refinement),cross-linking experiments, fluorescence spectroscopy, rules of secondary 
structure packing (combinatorial modeling),image reconstruction in electron microscopy, 
homologous structures (comparative modeling),site-directed mutagenesis, residue-residue 
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and atom-atom potentials of mean force, etc. Modeller is not an automated homology 
modelling tool[26]. 
It is a very specific program. Any error in the format of the sequence alignment prevents 
the modeller from performing Homology Modeling. The program is very specific about 
the extension names of the file formats used for Homology Modeling. It is a very reliable 
program and it allows the user to specify what he wants in the end result. Modeller runs on 
platforms like Win XP, Linux, Sun Solaris and Macintosh.  
DeepView - Swiss-PdbViewer is an application that provides a user friendly interface 
allowing to analyze several proteins at the same time. The proteins can be superimposed in 
order to deduce structural alignments and compare their active sites or any other relevant 
parts. Amino acid mutations, H-bonds, angles and distances between atoms are easy to 
obtain thanks to the intuitive graphic and menu interface. DeepView - Swiss-PdbViewer 
has been developped by Nicolas Guex (GlaxoSmithKline R&D). Swiss-PdbViewer is 
tightly linked to SWISS-MODEL, an automated homology modeling server developed 
within the Swiss Institute of Bioinformatics (SIB) at the Structural Bioinformatics Group 
at the Biozentrum in Basel[27]. 
3.4 Structure Analysis and Verification Server 
PROCHEK Checks the stereochemical quality of a protein structure by analyzing 
residue-by-residue geometry and overall structure geometry. It is tell about: Covalent 
geometry, Planarity, Dihedral angles, Chirality, Non-bonded interactions[28]. 
WHAT_CHEK derived from a subset of protein verification tools from the WHATIF 
program; this does extensive checking of many sterochemical parameters of the residues 
in the model[29]. 
DOPE: The DOPE model score is designed for selecting the best structure from a collection of 
models built by MODELLER. DOPE uses the standard MODELLER energy function. 
ERRAT is a protein structure verification algorithm that is especially well-suited for 
evaluating the progress of crystallographic model building and refinement. The program 
works by analyzing the statistics of non-bonded interactions between different atom types. 
A single output plot is produced that gives the value of the error function vs. position of a 
9-residue sliding window. By comparision with statistics from highly refined structures, 
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the error values have been calibrated to give confidence limits. ERRAT will give an 
“overall quality factor” and if it is a   high 90% range protein structure is good. This is 
extremely useful in making decisions about reliability[30]. 
VERIFY_3D determines the compatibility of an atomic model (3D) with its own amino 
acid sequence (1D) by assigned a structural class based on its location and environment 
(alpha, beta, loop, polar, nonpolar etc) and comparing the results to good structures. Then 
a database generated from vetted good structures is used to obtain a score for each of the 
20 amino acids in this structural class. For each residue, the scores of a sliding 21-residue 
window (from -10 to +10) are added and plotted[31]. 
PROVE Calculates the volumes of atoms in macromolecules using an algorithm which 
treats the atoms like hard spheres and calculates a statistical Z-score deviation for the 
model from highly resolved (2.0 Å or better) and refined (R-factor of 0.2 or better) PDB-
deposited structures[32]. 
3.5 Protein Active Site Prediction Tools 
CASTp: Computed Atlas of Surface Topography of proteins (http://cast.engr.uic.edu.) 
provides an online resource for locating, delineating and measuring concave surface 
regions on three-dimensional structures of proteins. These include pockets located on 
protein surfaces and voids buried in the interior of proteins. The measurement includes the 
area and volume of pocket or void by solvent accessible surface model and by molecular 
surface model, all calculated analytically. CASTp can be used to study surface features 
and functional regions of proteins. CASTp includes a graphical user interface, flexible 
interactive visualization, as well as on the- fly calculation for user uploaded structures 
[33]. 
PASS: Putative Active Sites with Spheres is a simple computational tool that uses 
geometry to characterize regions of buried volume in proteins and to identify positions 
likely to represent binding sites based upon the size, shape, and burial extent of these 
volumes[34].. PASS’S utility as a predictive tool for binding site identification is tested by 
predicting known binding sites of proteins in the PDB using both complexed 
macromolecules and their corresponding apo-protein structures. The results indicate that 
PASS can serve as a front-end to fast docking. The main utility of PASS lies in the fact 
that it can analyze a moderate-size protein (~ 30 kD) in under twenty seconds, which 
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makes it suitable for interactive molecular modeling, protein database analysis, and 
aggressive virtual screening efforts.  
As a modeling tool, PASS 
 (i) Rapidly identifies favorable regions of the protein surface,  
(ii) Simplifies visualization of residues modulating binding in these regions, and 
(iii) Provides a means of directly visualizing buried volume, which is often inferred 
indirectly from curvature in a surface representation.  
PASS produces output in the form of standard PDB files, which are suitable for any 
modeling package, and provides script files to simplify visualization.  
3.6 Docking Tools 
Autodock 4.0  
Autodock is used to perform computational molecular docking of small molecules to 
proteins, DNA, RNA and other important macromolecules, by treating the ligand and 
selected parts of the target as conformationally flexible. It uses a scoring function based on 
the AMBER force field, and estimates the free energy of binding of a ligand to its target. 
Novel hybrid global-local evolutionary algorithms are used to search the phase space of 
the ligand-macromolecule system.  
The introduction of Autodock 4 comprises three major improvements: 
1. The docking results are more accurate and reliable.  
2. It can optionally model flexibility in the target macromolecule.  
3. It enables Autodesk’s use in evaluating protein-protein interactions. 
Autodock 4 offers many new features and improvements over previous versions. The most 
significant is that it models flexible side chains in the protein. We can get both the 3D 
structure and the inhibition constants. 
AutoDock4 scoring functions are van der Waals forces, Hydrogen Bonding, Electrostatics, 
Desolvation, Torsional. 
Binding energy=Intermolecular energy +Torsional energy  
∆Gbind = ∆Gvdw + ∆Gele.  + ∆GH-bond + ∆G desolv +∆Gtors  
 Here ∆G=change in free energy 
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MATERIALS AND METHODS:  
4.1 Identification Novel Drug Targets: 
Whole genome sequences were downloaded for Chlamydophila pneumoniae (C. 
pneumoniae AR39, C. pneumoniae J138, C. pneumoniae TW1839, C. pneumoniae CWl029) 
[35].from National Center for Biotechnology Information (NCBI) center 
[ftp://ftp.ncbi.nlm.nih.gov/genomes/bacteria/]. The strains having a circular genome with 
1052-1112 predicted protein coding sequences. From the complete genome sequence data, 
the genes that code for proteins whose sequence were greater than 100 amino acids were 
selected out. These selected genes were subjected to BLASTX (parameter Matrix: 
BLOSUM62, Gap Penalties: Existence-11, Extension-1) against the DEG 
(http://tubic.tju.edu.cu.deg). A random expectation value (E-value) cut-off of 10 ^100 and 
a minimum bit-score cut-off of 100 was used to screen out genes that appeared to represent 
essential genes [36]. The screened essential genes of Chlamydophila pneumoniae were thus 
subjected to BLASTX against the human genome. The homologs were excluded and the list 
of non-homologs was compiled. The identified genes were than classified into different 
groups based on gene name and biological function, with the Swiss-Prot Protein Database 
(http://us.expasy.org/sprot), KEGG database[37]. The classified genes with same function 
were further analyzed to find homologs conserved genes with in all four C. pneumoniae 
strains. 
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Fig.4: Flowchart for identification of novel drug targets. 
4.2 Homology Modeling:  
The homologs conserved protein coding sequence i.e DNA helicase Ruv-B was selected 
from C. pneumoniae strains for drug target [38, 39]. The three-dimensional structure of 
DNA helicase Ruv-B protein was modeled by considering the suitable well studied template 
proteins structure were identified by similarity search with the BLAST tool against the 
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protein databank. The homology modeling is done online software like Geno3D, Swiss 
model, CPHmodels by using different parameter. And offline homology modeling is done 
using deep view , priory the modeled protein was refined by the MODELER 9v2. The 
model was validated for the 3D-1D profile with VERIFY3D, and the stereochemical 
qualities were checked with PROCHECK, Errat, Prove and WHAT_IF 
(http://nihserver.mbi.ucla.edu/SAVS/).  Finally, the structural properties of the target protein 
were validated by using the Ramachandran plot score. The different software models are 
compared with each other final best model is selected; it is used for further drug design 
process.  
4.3 Active site identification: 
Active sites of the target protein (DNA helicase Ruv-B) were predicted by using tools like 
PASS, CASTp which would be the key factor for the flexible docking. This provides 
resource for locating, delineating and measuring concave surface regions on three-
dimensional structures of proteins. These include pockets located on protein surfaces and 
voids buried in the interior of proteins that are frequently associated with binding events. In 
addition, it measures the size of mouth openings of individual pockets, for better 
accessibility of binding sites to various ligands and substrates. 
4.4 Ligand optimization and Docking: 
Optimization of leads was done based on the Lipinski rule of five [40]. The ligand 3D 
structure is minimized with ACD labs chemsk 10.0(www.acdlabs.com)[41]. These 
optimized ligands are used to find its respective interactions with the target protein. The 
docking of the ligands with the target protein was done by using the Autodock 4.0. Prepare 
files like pbdqt for Ligands and Protein, map files for protein. Generate Grid box near to 
binding site of protein. Choose the Lamarckian genetic algorithm to search for the best 
conformers [42]. During the docking process, the docking parameters was set to, Maximum 
Number of GA runs 100, Population size of 150, Maximum number of evaluation 250000, 
Rate of Gene mutation 0.02 for each Compound. The parameters were set using the software 
Autodock Tools. The Calculations of Autogrid and Autodock were performed on Linux 
operating system having system properties (Intel(R) Pentium(R) D CPU 2.80GHz, 2.0 GB 
of RAM). 
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RESULTS AND DISCUSSION:  
5.1 Identification of novel drug targets: 
Whole genome sequence of the human pathogen C. pneumoniae and four other strains of 
same species were analyzed to identify drug targets. Total number 4388 protein coding 
genes were studied from four strains (C. pneumoniae AR39, C. pneumoniae J138, C. 
pneumoniae TW1839, C. pneumoniae CWl029) via an in silico genomic approach.; in 
which 3948 genes were having more than 100 amino acids in their coding sequence were 
selected; this was on the assumption that proteins less than 100 amino acids known to able 
to affect the catalytic activity of proteins and participate in protein complex formation which 
affect their enzyme activity [43]. 
Table 2: Computational results of Chlamydophila pneumoniae. 
                  Chlamydophila pneumoniae 
C.P_AR39 C.P_CWL029 C.P_J138 C.P_TW183 
Total  number  of  protein  coding  
genes    
1112 1052 1069 1155 
Genes where products are > 100 
amino acids 
961 970 977 1040 
Genes where products are <100  
amino acids 
151 82 92 115 
Essential genes having non-human 
homologs 
31 47 35 34 
 
5.2 Sequence analysis Sample results: 
  The query gene sequences BLASTX against DEG(database for essential genes ) with 
blastX with parameter Matrix: BLOSUM62,Gap Penalties: Existence: 11, Extension: 1 
DEG BLASTX output: 
Query= ref|NC_002179.2|:201-1199 
         (999 letters) 
Database: deg.aa  
           4509 sequences; 1,713,232 total letters 
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                                                                 Score    E 
Sequences producing significant alignments:                      (bits) Value 
 
15927247_1  DEG10020269  Staphylococcus aureus,hemB,        ...   235   5e-63 
b0369_1  DEG10040070  Escherichia coli MG1655,hemB,         ...   229   4e-61 
15608158_1  DEG10090155  Mycobacterium tuberculosis H37Rv,gl...    26   4.7   
MG468_1  DEG10060378  Mycoplasma genitalium,MG468,          ...    26   4.7   
 
From above  results , the score >100 identified  as essential gene (our query 
sequence). These gene also blast with NMPDR ,the results are further blast against human 
protein sequences by using blast with default parameters. The results are shown below, from 
this the score <60, query sequence is taken as non-human homologs gene. This genes are 
known as a potential therapeutic targets. These gene are further classified in to different 
groups based on function. 
NCBI BLASTX output:  
Query=  ref|NC_005043.1|:779091-779924 
Length=834 
 
Database: Homo sapiens RefSeq protein 
           13,039 sequences; 4,940,105 total letters 
 
Fig. 5: Graphical output of BLASTX results. 
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Fig.6:  The graph showing non-human homologs essential genes encoding different proteins 
involved in a same biological function in comparison with four different strains.    
147 genes were identified as non-human homologs and conserved proteins among four 
strains (Tab.2). These non-human homologs genes and their encoding protein were further 
categorized on the basis of the pathways involved in the basic survival mechanisms such as: 
genes belong to the DNA replication, recombination, modification and repair, translation 
and post translation modification, transport of small molecule, transcription, RNA 
processing  and degradation. i. e. any disruption in the functioning of those genes will lead 
to bacterial death (Fig. 6). The pathway information for each target gene was obtained from 
the KEGG database. These essential genes were covering 3-4% of total genome of the 
organism. In MSA analysis we identified conserved regions among the protein sequences 
having same biological function (Tab.3). All such essential genes can be potential drug 
targets but including those genes whose  products have sequence similarities with any 
human protein may lead to drug reactions with the host and, thus, to toxic effects. Therefore, 
homology modeling was done only with the DNA helicase RuvB protein encoding genes, 
which have no sequence similarities with the human genes. 
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Table 3:  The predicted drug targets of Chlamydophila pneumoniae. 
S.no Protein name Function of protein 
1 excinuclease ABC subunit A DNA Replication, Recombination, modification 
and Repair 
2 Holliday junction DNA helicase 
RuvB 
DNA Replication, Recombination, modification 
and Repair 
3 30S ribosomal protein S10 Translation ,post  modification 
4 30S ribosomal protein S2 Translation ,post modification 
5 GTP-binding protein EngA     GTP-dependent binding, GTPase 
 of unknown physiological role. 
6 hypothetical protein hypothetical function 
7 Acetyl glucosaminyl transferase acetylglucosaminyl transferase 
8 riboflavin-specific deaminase Putative enzymes 
 
5.3 Homology Modelling Results: 
Three-dimensional structures will help in the identification of binding sites and may 
lead to the designing of new drugs. The 3D structure of DNA helicase RuvB protein of the 
C. pneumoniae was modeled with Deep View; CPHmodels; Geno3D; Swiss model; 
MODELLER9v2 was used for fine building the model and global energy minimization. 
Table4: homology modelling best results of different softwares of target protein. 
S.no protein Procheck Verify3D Errat 
1 Geno3Dmodel 75.7 87.18 95.03 
2 Deep view model 93.9 92.53 84.12 
3 Modeller model 94.2 92.90 80.80 
4 CPHmodels 90.5 95.13 92.51 
5 Swiss model 90.6 88.17 89.91 
 
 The above table shows the modeller showing better results than deepview, Swiss 
model. Modeller is the one of best homology modelling software. The details of Modeller results 
are explained below in details. 
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Results of modeller:  
 
Fig. 7: clustering tree (dendrogram) from pairwise distance matrix . 
The comparison above shows that 1hqc:A[44] and 1in4:A[45]  are almost identical, 
both sequentially and structurally. However, 1in4:A has a better crystallographic resolution 
(3.6Å versus 1.6Å), eliminating 1hqc:A. A second group of structures (1iqp:A[46], 1sxj:c[47]) 
share some similarities. From this group, 1sxj has the poorest resolution leaving for 
consideration only 1iqp:A. 3cf2:A[48],  is the most diverse structure of the whole set of 
possible templates. However, it is the one with the lowest sequence identity (26%) to the 
query sequence. We finally pick 1in4:A over 1iqp:A because of its better resolution versus 
1.6Å , ts better crystallographic R-factor (23.4%) and higher overall sequence identity to the 
query sequence (53%). 
         Table 5: Detail known structure protein with target sequence. 
Protein id Identity E-value Resolution( Ao) R-value 
1e32:A 33 0.63E-02 2.90  0.224 
1hqc:A 50 0 3.20  0.263 
1in4:A 53 0 1.60  0.234 
1iqp:A 26 0.52E-04 2.80  0.224 
1sxj:C 50 0.90E-03 2.85  0.251 
1sxj:D 49 0.20E-02 2.85  0.251 
1ypw:A 26 0.40E-02 3.50  0.271 
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Fig 8: The template(1in4:A) and target protein sequence alignment PAP alignment format. 
The above five model are generated by modeller, the "best" model can be selected in 
several ways.  The best model selected with the lowest value of the MODELLER objective 
function, the DOPE assessment score, with the highest percentage residue core region from 
Ramachandran plot and highest overall quality factor  Errat, all of which are reporting the 
model one good  structure of target protein. The molpdf and DOPE scores are not 'absolute' 
measures, in the sense that they can only be used to rank models calculated from the same 
alignment. Other scores are transferable.  
Table 6: Summary of successfully produced models by single template model 
S.n
o 
Protein 
model 
Procheck 
(Ramachandra
n plot: % core) 
Verify3D 
(% of the 
residues had an 
averaged 3D-
1D score > 0.2) 
Errat 
(Overal
quality 
factor) 
Mol pdf 
score 
Dope 
score 
Final 
rank  
1 Rnb1 94.2 86.09 85.67 1294.64 -36710.75 1 
2 Rnb2 92.8 87.87 73.354 1316.65 -36555.46 3 
3 Rnb3 93.8 83.73 78.89 1354.76 -36460.83 4 
4 Rnb4 92.5 85.5 77.88 1458.02 -37035.18 5 
5 Rnb5 94.2 87.87 78.638 1584.59 -36610.44 2 
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The above table analysis, confirms that model1 (Rnb1) is a reasonable model. 
However, the plotted DOPE score profile (below) shows regions of relatively high energy 
for the long active site loop between residues 194 and 205 and the long helices at the C-
terminal end of the target sequence.  
 
Fig 9: DOPE score profile for single template model1(Rnb1) and template 1in4. 
The selected model is further refining with multiple templates and final Modeling 
loop using ab-initio methods. The structure of the 1in4 has been clustered in the DBAli 
database (http://salilab.org/DBAli/) within the family fm03090 of 2 members 
(1ixr:C,1in6:A). The multiple alignment generated by the with MODELLER.  
Fm03090 family tree:  
        .---------------------------------------------------------- 1ixrC          0.6590 
        | 
        |                                                      .--- 1in4A          0.0762 
        |                                                      | 
      .------------------------------------------------------------ 1in6A      
 
      +----+----+----+----+----+----+----+----+----+----+----+----+ 
     0.6823    0.5774    0.4725    0.3676    0.2627    0.1578    0.0528 
          0.6299    0.5250    0.4201    0.3151    0.2102    0.1053 
Fig.10: Fm03090 family tree 
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Fig.11: The multiple structure alignment generated with MODELLER in PIR format. 
Five model are generated with multiple structure alignment among  these five 
models model1(Rnm1) showing high overall quality. The evaluation of the model indicates 
that the problematic loop (residues 194 to 205) has improved by using multiple structural 
templates. The global DOPE score for the models also improved from -36710.75 to -
37227.23. MODELLER was able to use the variability in the loop region from the three 
templates to generate a more accurate conformation of the loop. However, the conformation 
of a loop in the region around the residue 46 at the C-terminal end of the sequence has 
higher DOPE score than for the model based on a single template. 
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Table 7: Results of modeling target protein with multiple templates. 
S.n
o 
Protein 
model 
Procheck 
(Ramachan
dran plot: 
% core) 
Verify3D 
(% of the 
residues had an 
averaged 3D-1D 
score > 0.2) 
Errat 
(Overall 
quality 
factor) 
Mol pdf 
score 
Dope 
score 
Final 
rank  
1 Rnm1 94.2 92.31 80.625 9915.50 -37227.23 1 
2 Rnm2 92.8 77.81 78.704 9922.36 -37316.92 4 
3 Rnm3 93.5 87.28 80.435 9869.65 -37073.76 2 
4 Rnm4 93.2 85.80 77.329 10459.26 -36820.12 5 
5 Rnm5 92.8 85.21 77.064 9834.48 -37234.64 3 
 
 
Fig.12: DOPE score profile for single template model1(Rnb1), multi template 
model1(Rnm1), loop refine model8(Rnl8). 
Loop refining 
The loop between residues 44 and 51 is refining with modeller. The 10 different model are 
generated with MODELLER among these 8th model (Rnl8) showing good structural quality. 
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Table 8: Results of modeling target protein with loop refining. 
S.no Protein 
model 
Procheck 
(Ramachandran 
plot: % core) 
Verify3D 
(% of the 
residues had 
an averaged 
3D-1D 
score > 0.2) 
Errat 
(Overall 
quality 
factor) 
Mol 
pdf 
score 
Final 
rank 
1 Rnl1 94.2 92.9 80.805 28.88 4 
2 Rnl2 92.8 92.31 77.50 38.05 10 
3 Rnl3 93.8 92.31 80.312 37.81 9 
4 Rnl4 93.8 92.31 80.938 22.94 5 
5 Rnl5 93.8 92.31 80.625 42.86 6 
6 Rnl6 93.8 92.90 81.25 28.87 3 
7 Rnl7 94.2 92.90 79.439 42.36 7 
8 Rnl8 94.2 92.90 80.938 26.98 1 
9 Rnl9 93.8 92.90 79.814 30.38 8 
10 Rnl10 94.2 92.31 80.435 31.25 2 
 
Final Total Energy of protein: -10633.516 KJ/mol. The final structure of protein is 
shown in fig.13. Homology modeling is only a viable technique because it produces models 
that can be used for further research. The structure of the target protein is structurally similar 
with the template if both the target and template sequences are similar. In general, above 
40% sequence homology is required for generating useful models. 
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a) Modeled protein ribbon structure.       b) Modeled protein surface structure.  
Fig.13: Predicted 3-D structure of Holliday junction DNA helicase RuvB protein 
The modeled protein is validated with SAVES (Structure Analysis and Verification 
Server) it is located at NIH MBI Laboratory for Structural Genomics and Proteomics. The 
total energy values of the predicted 3-D model were calculated as 93.9% of Ramachandran 
plot (Fig. 14) value in 30 and 40 steepest descents and conjugate gradient, respectively. 
 
 
Plot statistics 
 
Residues in most favoured regions [A,B,L]          248       93.9% 
Residues in additional allowed regions [a,b,l,p]     16        6.1% 
Residues in generously allowed regions [~a,~b,~l,~p] 0    0.0% 
Residues in disallowed regions                                         0 0.0% 
---- ------------------------------------------------------------------------ 
Number of non-glycine and non-proline residues 264     100.0% 
Number of end-residues (excl. Gly and Pro)            2 
Number of glycine residues (shown as triangles)   28 
Number of proline residues                                    13 
----------------------------------------------------------------------------- 
Total number of residues                                      307 
----------------------------------------------------------------------------- 
M/c bond lengths: 99.3%  within limits     0.7%  highlighted        
M/c bond angles:  98.2%  within limits      1.8%  highlighted                   
Planar groups:        87.4%  within limits   12.6% highlighted   
 
Fig.14: Ramachandran plot of Holliday junction DNA helicase RuvB protein from 
PROCHECK. 
Errat analyzes the statistics of non-bonded interactions between different atom types 
and plots the value of the error function versus position of a residue. From Errat Overall 
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quality factor 84.122. Verify_3D determines the compatibility of an atomic model (3D) with 
its own amino acid sequence (1D) by assigned a structural class based on its location and 
environment (alpha, beta, loop, polar, nonpolar etc) and comparing the results to good 
structures. Verify_3D results shows 92.53% of the residues had an averaged 3D-1D score 
>0.2 and test passed. (See supplementary material 2 for the of the corresponding Structure 
validation results) 
5.4 Active site prediction and docking study: 
Active sites of the target protein were predicted by PASS, CASTp active site 
prediction tools. The feasible active sites predicted by the tools are as follows. 
 
Fig.15: Visualization predicted active site binding pocket of target protein with void volume  
162, area 208.9. 
The feasible active sites: 
   20PRO       49VAL      51GLY        58PRO       60 GLY    
   65SER        70VAL       74VAl      101GLU      104VAL      
151THR      157THR     177SER      179TYR       187ILE      
219ASN      223ARG     294ASP      308LYS 
Optimization of leads was done based on the Lipinski rule of five, in this poorly soluble 
compounds or compounds with poorer physical and chemical properties, as well as insoluble 
and non-permeable compounds would have been filtered out at earlier stages. The Molecular 
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weight known relationship between poor permeability and high molecular weight, number of 
hydrogen bond donors and acceptors – High numbers may impair permeability across 
membrane bilayer. the selected ligand are their properties are shown in Tab.3  
Table 9: ligand properties are collected from NCBI Pubchem Compound database. 
S.no Formula ID MW  
g/mol 
A* TPSA B*  C* D     D* 
1 C6H14O2 452860 118.17 0.2 40.5 2 2 5 
2 C5H5N5 190 135.13 -0.3 80.5 2 5 0 
3 C10H17N 2130 151.25 2.3  1 1 0 
4 C16H19N3O5S 33613 365.40 0 133 4 6 4 
5 C7H7NO3 134085 153.13 -0.5 57.6 1 3 1 
6 C14H18N4O3 5578 290.32 0.6 106 2 7 5 
7 C10H11N3O3S 5329 253.28 0.7 98.2 2 6 3 
8 C8H5BrO4S 6475860 277.09 0.9 74.6 2 4 3 
9 C14H18O4 6475859 250.29 3 74.6 2 4 3 
10 C15H13NO5 5482292 287.27 1.9 99.8 3 6 5 
11 C18H11Cl2NO5 5482291 392.18 4 108 4 6 6 
 
A*- Octanol-water partition coefficient (XLogP)  
TPSA - Topological polar surface area 
MW - Molecular weight 
B*- Hydrogen bond donors 
C*- Hydrogen bond acceptors 
D* - Number of rotatable bonds 
These optimized ligands are used to find its respective interactions with the targeted protein 
by using the lamarkian genetic algorithm which gives the best 100 best possible interactions 
with the least binding energy.  
The Docking was performed with all ligands to the target protein, below Table10 shows the 
different flexible conformation of ligands indicated by the run that binds to the target binding 
site with the respective binding energy. Among all the ligand compound, compound having id  
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5482291 was found to having lowest binding free energy -8.99 Kcal/mol and may considered 
potential lead for further investigation. It is binding to the predicted active site Ser177, 
Asn219 with lowest binding free energy , number of distinct conformational clusters found = 
58, out of 100 runs, Using an rmsd-tolerance of 2.0 A and the sample result is shown below 
Cluster Rank = 1                                   Run = 65 
Number of conformations in this cluster = 9 
RMSD from reference structure       = 72.644 A 
Estimated Free Energy of Binding    = -8.99 kcal/mol [= (1)+(2)+(3)-(4)] 
Estimated Inhibition Constant, Ki   = 258.24 nM (nanomolar) [Temp= 298.15 K] 
  (1) Final Intermolecular Energy   =  -10.94 kcal/mol 
      vdW + Hbond + desolv Energy   =   -8.54 kcal/mol 
       Electrostatic Energy         =   -2.39 kcal/mol 
  (2) Final Total Internal Energy   =   -0.45 kcal/mol 
  (3) Torsional Free Energy         =   +2.20 kcal/mol 
  (4) Unbound System's Energy       =   -2.20 kcal/mol  
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Table 10: The binding free energy of  DNA helicase RuvB protein with different compound 
and conformations. 
S.no Pubchem  
Compound  
ID 
Binding site Chemical 
Formula 
Binding 
energy(Kcal/mol) 
Run Rank 
1 5482291 SER177,ASN219 C18H11Cl2NO5 -8.99 65 1 
2 5329 PRO58,THR157 C10H11N3O3S -7.63 86 2 
3 5482292 GLY60 C15H13NO5 -7.28 38 3 
4 6475859 ASP294 C14H18O4 -7.24 86 4 
5 6475860 GLY60,SER65 C8H5BrO4S -6.95 25 5 
6 134085 ASN219,187ILE C7H7NO3 -6.01 4 6 
7 33613 ASP294 C16H19N3O5S -5.78 56 7 
8 5578 ASN219,187ILE C14H18N4O3 -5.28 62 8 
9 190 GLY60 C5H5N5 -4.37 59 9 
10 2130 PRO20 C10H17N -4.00 24 10 
11 452860 THR157 C6H14O2 -3.92 72 11 
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Conclusion 
The availability of full genome sequences and computer-aided software like 
modeler, Autodock help to identify probable antimicrobial drug targets to dock with protein 
targets, it has become a new trend in bioinformatics. C. pneumoniae is a multi-drug resistant 
bacterium and causes severe infection in humans. Active compound like 5482291 targeted 
to Holliday junction DNA helicase RuvB protein will be particularly useful in overcoming 
the detrimental consequence of C. pneumoniae infection. We present here a detailed in silico 
analysis of essential genes, Molecular Modeling of the target protein and followed by lead 
optimization that favours the docking. This paper present a detailed in silico thus the 
docking analysis proves the 5482291 is an active compound that binds to the targeted 
Holliday junction DNA helicase RuvB protein with the least binding energy.  
On further study for the pharmacodynamic, pharmacokinetics, solubility and 
thermodynamics activity of these ligand receptor binding can inhibit the pathogenic activity 
of the organism. 
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